Comparative utility of aripiprazole and haloperidol in schizophrenia

Post hoc analysis of two 52-week, randomized, controlled trials

John M. Kane, Edward Kim, Hongjun Kan, Zhenchao Guo, John A. Bates, Richard Whitehead, Andrei Pikalov

Research output: Contribution to journalArticle

Abstract

Background: Since their introduction, second-generation antipsychotics (SGAs) have become the drugs of choice for the treatment of schizophrenia. However, recent findings have questioned the benefits of SGAs over first-generation antipsychotics (FGAs). Objective: This post hoc analysis sought to compare the utility of the SGA aripiprazole with the FGA haloperidol in patients with early-phase schizophrenia (ES) or chronic schizophrenia (CS). Method: Data were pooled from two identical 52-week, randomized, active comparator trials (31-98-217 and 31-98-304) of aripiprazole 20-30 mg/day versus haloperidol 7-10 mg/day. Patients in the efficacy sample were classified as having ES if they were 40 years of age with a duration of illness 5 years. All other patients were classified as having CS. Health-state utilities were derived from the Positive and Negative Syndrome Scale and adverse events, using the last observation carried forward method. Results: Of 1294 patients in the efficacy sample, 362 met criteria for ES (aripiprazole, n= 239; haloperidol, n= 123) and 932 met criteria for CS (aripiprazole, n= 622; haloperidol, n = 310). Baseline patient characteristics were similar between treatment arms. At week 52, patients treated with aripiprazole in the total and ES populations had significantly greater total utility than those treated with haloperidol, although there were no statistically significant differences in total utility for the CS population at week 52. For the total population, patients treated with aripiprazole had significantly higher quality-adjusted life days (QALDs)/year than haloperidol recipients (+6.48 QALDs/year, p= 0.02). Significantly higher QALDs/year were also seen for aripiprazoletreated patients with ES (+10.65 QALDs/year, p = 0.04) but not for patients with CS (+4.92 QALDs/year, p= 0.14), compared with haloperidol-treated patients. Conclusions: Aripiprazole demonstrates greater utility than haloperidol over 52 weeks of treatment. This difference was driven by superiority of aripiprazole over haloperidol in patients with ES, which was not observed in patients with CS.

Original languageEnglish (US)
Pages (from-to)109-119
Number of pages11
JournalApplied Health Economics and Health Policy
Volume7
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Haloperidol
Schizophrenia
Randomized Controlled Trials
Quality-Adjusted Life Years
Antipsychotic Agents
Aripiprazole
Randomized controlled trial
Population
Therapeutics
Observation

ASJC Scopus subject areas

  • Economics and Econometrics
  • Health Policy

Cite this

Comparative utility of aripiprazole and haloperidol in schizophrenia : Post hoc analysis of two 52-week, randomized, controlled trials. / Kane, John M.; Kim, Edward; Kan, Hongjun; Guo, Zhenchao; Bates, John A.; Whitehead, Richard; Pikalov, Andrei.

In: Applied Health Economics and Health Policy, Vol. 7, No. 2, 2009, p. 109-119.

Research output: Contribution to journalArticle

Kane, John M. ; Kim, Edward ; Kan, Hongjun ; Guo, Zhenchao ; Bates, John A. ; Whitehead, Richard ; Pikalov, Andrei. / Comparative utility of aripiprazole and haloperidol in schizophrenia : Post hoc analysis of two 52-week, randomized, controlled trials. In: Applied Health Economics and Health Policy. 2009 ; Vol. 7, No. 2. pp. 109-119.
@article{132b5363a3cf4de69db8a0f2e2eb4500,
title = "Comparative utility of aripiprazole and haloperidol in schizophrenia: Post hoc analysis of two 52-week, randomized, controlled trials",
abstract = "Background: Since their introduction, second-generation antipsychotics (SGAs) have become the drugs of choice for the treatment of schizophrenia. However, recent findings have questioned the benefits of SGAs over first-generation antipsychotics (FGAs). Objective: This post hoc analysis sought to compare the utility of the SGA aripiprazole with the FGA haloperidol in patients with early-phase schizophrenia (ES) or chronic schizophrenia (CS). Method: Data were pooled from two identical 52-week, randomized, active comparator trials (31-98-217 and 31-98-304) of aripiprazole 20-30 mg/day versus haloperidol 7-10 mg/day. Patients in the efficacy sample were classified as having ES if they were 40 years of age with a duration of illness 5 years. All other patients were classified as having CS. Health-state utilities were derived from the Positive and Negative Syndrome Scale and adverse events, using the last observation carried forward method. Results: Of 1294 patients in the efficacy sample, 362 met criteria for ES (aripiprazole, n= 239; haloperidol, n= 123) and 932 met criteria for CS (aripiprazole, n= 622; haloperidol, n = 310). Baseline patient characteristics were similar between treatment arms. At week 52, patients treated with aripiprazole in the total and ES populations had significantly greater total utility than those treated with haloperidol, although there were no statistically significant differences in total utility for the CS population at week 52. For the total population, patients treated with aripiprazole had significantly higher quality-adjusted life days (QALDs)/year than haloperidol recipients (+6.48 QALDs/year, p= 0.02). Significantly higher QALDs/year were also seen for aripiprazoletreated patients with ES (+10.65 QALDs/year, p = 0.04) but not for patients with CS (+4.92 QALDs/year, p= 0.14), compared with haloperidol-treated patients. Conclusions: Aripiprazole demonstrates greater utility than haloperidol over 52 weeks of treatment. This difference was driven by superiority of aripiprazole over haloperidol in patients with ES, which was not observed in patients with CS.",
author = "Kane, {John M.} and Edward Kim and Hongjun Kan and Zhenchao Guo and Bates, {John A.} and Richard Whitehead and Andrei Pikalov",
year = "2009",
doi = "10.2165/11314800-000000000-00000",
language = "English (US)",
volume = "7",
pages = "109--119",
journal = "Applied Health Economics and Health Policy",
issn = "1175-5652",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Comparative utility of aripiprazole and haloperidol in schizophrenia

T2 - Post hoc analysis of two 52-week, randomized, controlled trials

AU - Kane, John M.

AU - Kim, Edward

AU - Kan, Hongjun

AU - Guo, Zhenchao

AU - Bates, John A.

AU - Whitehead, Richard

AU - Pikalov, Andrei

PY - 2009

Y1 - 2009

N2 - Background: Since their introduction, second-generation antipsychotics (SGAs) have become the drugs of choice for the treatment of schizophrenia. However, recent findings have questioned the benefits of SGAs over first-generation antipsychotics (FGAs). Objective: This post hoc analysis sought to compare the utility of the SGA aripiprazole with the FGA haloperidol in patients with early-phase schizophrenia (ES) or chronic schizophrenia (CS). Method: Data were pooled from two identical 52-week, randomized, active comparator trials (31-98-217 and 31-98-304) of aripiprazole 20-30 mg/day versus haloperidol 7-10 mg/day. Patients in the efficacy sample were classified as having ES if they were 40 years of age with a duration of illness 5 years. All other patients were classified as having CS. Health-state utilities were derived from the Positive and Negative Syndrome Scale and adverse events, using the last observation carried forward method. Results: Of 1294 patients in the efficacy sample, 362 met criteria for ES (aripiprazole, n= 239; haloperidol, n= 123) and 932 met criteria for CS (aripiprazole, n= 622; haloperidol, n = 310). Baseline patient characteristics were similar between treatment arms. At week 52, patients treated with aripiprazole in the total and ES populations had significantly greater total utility than those treated with haloperidol, although there were no statistically significant differences in total utility for the CS population at week 52. For the total population, patients treated with aripiprazole had significantly higher quality-adjusted life days (QALDs)/year than haloperidol recipients (+6.48 QALDs/year, p= 0.02). Significantly higher QALDs/year were also seen for aripiprazoletreated patients with ES (+10.65 QALDs/year, p = 0.04) but not for patients with CS (+4.92 QALDs/year, p= 0.14), compared with haloperidol-treated patients. Conclusions: Aripiprazole demonstrates greater utility than haloperidol over 52 weeks of treatment. This difference was driven by superiority of aripiprazole over haloperidol in patients with ES, which was not observed in patients with CS.

AB - Background: Since their introduction, second-generation antipsychotics (SGAs) have become the drugs of choice for the treatment of schizophrenia. However, recent findings have questioned the benefits of SGAs over first-generation antipsychotics (FGAs). Objective: This post hoc analysis sought to compare the utility of the SGA aripiprazole with the FGA haloperidol in patients with early-phase schizophrenia (ES) or chronic schizophrenia (CS). Method: Data were pooled from two identical 52-week, randomized, active comparator trials (31-98-217 and 31-98-304) of aripiprazole 20-30 mg/day versus haloperidol 7-10 mg/day. Patients in the efficacy sample were classified as having ES if they were 40 years of age with a duration of illness 5 years. All other patients were classified as having CS. Health-state utilities were derived from the Positive and Negative Syndrome Scale and adverse events, using the last observation carried forward method. Results: Of 1294 patients in the efficacy sample, 362 met criteria for ES (aripiprazole, n= 239; haloperidol, n= 123) and 932 met criteria for CS (aripiprazole, n= 622; haloperidol, n = 310). Baseline patient characteristics were similar between treatment arms. At week 52, patients treated with aripiprazole in the total and ES populations had significantly greater total utility than those treated with haloperidol, although there were no statistically significant differences in total utility for the CS population at week 52. For the total population, patients treated with aripiprazole had significantly higher quality-adjusted life days (QALDs)/year than haloperidol recipients (+6.48 QALDs/year, p= 0.02). Significantly higher QALDs/year were also seen for aripiprazoletreated patients with ES (+10.65 QALDs/year, p = 0.04) but not for patients with CS (+4.92 QALDs/year, p= 0.14), compared with haloperidol-treated patients. Conclusions: Aripiprazole demonstrates greater utility than haloperidol over 52 weeks of treatment. This difference was driven by superiority of aripiprazole over haloperidol in patients with ES, which was not observed in patients with CS.

UR - http://www.scopus.com/inward/record.url?scp=70149093748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149093748&partnerID=8YFLogxK

U2 - 10.2165/11314800-000000000-00000

DO - 10.2165/11314800-000000000-00000

M3 - Article

VL - 7

SP - 109

EP - 119

JO - Applied Health Economics and Health Policy

JF - Applied Health Economics and Health Policy

SN - 1175-5652

IS - 2

ER -